Panitumumab for advanced colorectal cancer - horizon scanning review
National Horizon Scanning Centre
Record ID 32005000233
English
Authors' objectives:
This study aims to assess the effectiveness of panitumumab for advanced colorectal cancer.
Authors' recommendations:
Panitumumab (ABX-EGF) is a monoclonal antibody in phase III trials as third- or fourth-line monotherapy in patients with advanced colorectal cancer who have failed previous fluoropyrimidine, irinotecan and/or oxaliplatin chemotherapy regimens. Panitumumab binds to the epidermal growth factor receptor (EGFR), blocking critical signalling pathways and inhibiting the growth of tumours expressing EGFR. A phase II trial in 148 patients demonstrated partial responses in around 10% of patients and stable disease in a third. Median duration of response was 5.2 months. Median overall time to progression was 2 months, and median overall survival was 7.9 months.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
http://www.pcpoh.bham.ac.uk/publichealth/horizon/
Year Published:
2005
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antibodies, Monoclonal
- Antineoplastic Agents
- Colorectal Neoplasms
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.